- Home
- LANV vs LCTX Comparison
LANV vs LCTX Comparison
Compare LANV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- LCTX
- Stock Information
- Founded
- LANV 2015
- LCTX 1990
- Country
- LANV China
- LCTX United States
- Employees
- LANV N/A
- LCTX N/A
- Industry
- LANV Blank Checks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LANV Finance
- LCTX Health Care
- Exchange
- LANV Nasdaq
- LCTX Nasdaq
- Market Cap
- LANV 264.3M
- LCTX 274.0M
- IPO Year
- LANV N/A
- LCTX N/A
- Fundamental
- Price
- LANV $2.11
- LCTX $1.34
- Analyst Decision
- LANV
- LCTX Strong Buy
- Analyst Count
- LANV 0
- LCTX 4
- Target Price
- LANV N/A
- LCTX $4.25
- AVG Volume (30 Days)
- LANV 42.5K
- LCTX 1.6M
- Earning Date
- LANV 08-29-2025
- LCTX 11-13-2025
- Dividend Yield
- LANV N/A
- LCTX N/A
- EPS Growth
- LANV N/A
- LCTX N/A
- EPS
- LANV N/A
- LCTX N/A
- Revenue
- LANV $341,783,911.00
- LCTX $10,914,000.00
- Revenue This Year
- LANV $11.74
- LCTX N/A
- Revenue Next Year
- LANV $11.11
- LCTX $178.80
- P/E Ratio
- LANV N/A
- LCTX N/A
- Revenue Growth
- LANV N/A
- LCTX 76.43
- 52 Week Low
- LANV $1.32
- LCTX $0.37
- 52 Week High
- LANV $2.69
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- LANV 43.49
- LCTX 64.60
- Support Level
- LANV $1.81
- LCTX $1.20
- Resistance Level
- LANV $2.40
- LCTX $1.28
- Average True Range (ATR)
- LANV 0.15
- LCTX 0.07
- MACD
- LANV 0.00
- LCTX 0.00
- Stochastic Oscillator
- LANV 51.26
- LCTX 69.64
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.